Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for I-Mab Sponsored ADR (IMAB : NSDQ)

• Company Description    I-Mab is a clinical stage biopharmaceutical company. It engages in discovery, development and commercialization of biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders. I-Mab is based in SHANGHAI, China. Number of Employees: 228

• Price / Volume Information    Yesterday's Closing Price: $11.99 Daily Weekly Monthly 20 Day Moving Average: 1,426,557 shares Shares Outstanding: 82.65 (millions) Market Capitalization: $990.93 (millions) Beta: 1.02 52 Week High: $85.40 52 Week Low: $10.14 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -2.36% 6.99% 12 Week -55.13% -51.31% Year To Date -74.70% -69.91%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL SUITE 802 WEST TOWER OMNLVISION 88 SHANGKE ROAD PUDONG DISTRICT - SHANGHAI,F4 201210 CHN ph: 86-21-6057-8000 fax: - ir@i-mabbiopharma.com http://www.i-mabbiopharma.com/en

• General Corporate Information    Officers Joan Huaqiong Shen - Chief Executive Officer and Director Jingwu Zhang Zang - Chairman and Director Zheru Zhang - President and Director Jielun Zhu - Chief Financial Officer and Director Weimin Tang - Executive Vice President Peer Information I-Mab Sponsored ADR (CORR.) I-Mab Sponsored ADR (RSPI) I-Mab Sponsored ADR (CGXP) I-Mab Sponsored ADR (BGEN) I-Mab Sponsored ADR (GTBP) I-Mab Sponsored ADR (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 44975P103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: 82.65 Most Recent Split Date: (:1) Beta: 1.02 Market Capitalization: $990.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.20 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.34 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/22 - - 12/31/21 - - 09/30/21 - - ROA 03/31/22 - - 12/31/21 - - 09/30/21 - - Current Ratio 03/31/22 - - 12/31/21 - 7.66 09/30/21 - - Quick Ratio 03/31/22 - - 12/31/21 - 7.62 09/30/21 - - Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -2,652.32 09/30/21 - - Book Value 03/31/22 - - 12/31/21 - 8.95 09/30/21 - - Inventory Turnover 03/31/22 - - 12/31/21 - 1.70 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.00 09/30/21 - - Debt-to-Capital 03/31/22 - - 12/31/21 - 0.00 09/30/21 - -

Powered by Zacks Investment Research ©